No Data
No Data
Are Robust Financials Driving The Recent Rally In APT Medical Inc.'s (SHSE:688617) Stock?
Institutional Investors Are APT Medical Inc.'s (SHSE:688617) Biggest Bettors and Were Rewarded After Last Week's CN¥2.4b Market Cap Gain
HAITONG SEC: PFA Global intensive commercialization opens a new era in electrophysiology.
The domestic PFA system is more in line with the preferences of local doctors and is expected to overtake in the curve.
Returns on Capital Paint A Bright Future For APT Medical (SHSE:688617)
China Approves APT Medical Unit's Atrial Fibrillation Treatment Device
Research Reports Mining丨Guosheng Securities: APT Medical Inc.'s PFA products have good safety and effectiveness, maintaining a "Buy" rating.
Guosheng Securities' Research Reports pointed out that APT Medical Inc. (688617.SH) PFA product integrates three major functional characteristics, possessing good safety and efficacy. The company's PFA innovative product is the first in the Global to combine "pressure sensing / contact indication" + "magnetic定位三维标测" + "pulse ablation" into one ablation system, featuring unique technical advantages. The approval of the company's PFA products has enriched the product layout in the electrophysiology field, and there is Bullish outlook on Mindray's entry enabling the company's continuous research and development and sales at home and abroad. The proportion of China's atrial fibrillation pulsed electric field ablation Medical Devices in the cardiac electrophysiology devices will also continue to increase.